Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases

Current Medicinal Chemistry

Volumn 19, Issue 17, 2012, Pages 2667-2688

  Sarko, D ^a,b   Eisenhut, M ^c   Haberkorn, U ^a   Mier, W ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b AL BAATH UNIVERSITY   (Syrian Arab Republic)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Bifunctional chelating agent (BFCA); DOTA; Nuclear medicine; Radiochemistry; Radiometals; Radiopharmaceuticals; Targeting; Theranostics

Indexed keywords

1 (1 CARBOXY 3 CARBOXYPROPYL) 4,7 BIS(CARBOXYMETHYL) 1,4,7 TRIAZACYCLONONANE; 1,4,7 TRIAZACYCLONONANE 1 SUCCINIC ACID 4,7 DIACETIC ACID; BIFUNCTIONAL CHELATING AGENT; CHELATING AGENT; COPPER 60; COPPER 61; COPPER 62; COPPER 64; COPPER 67; DEPREOTIDE TC 99M; DOTATOC; GALLIUM 67; GALLIUM 68; IBRITUMOMAB TIUXETAN; INDIUM 111; INDIUM 113M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PENTETIC ACID; PENTETREOTIDE IN 111; PEPTIDE DERIVATIVE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; TECHNETIUM 99M; TETRAXETAN; TOSYLARGININE METHYL ESTER; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 86; YTTRIUM 90;

ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CARCINOID; CLICK CHEMISTRY; COLORECTAL CANCER; CONJUGATION; CYTOTOXICITY; DRUG HALF LIFE; ENDOCYTOSIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IONIZING RADIATION; ISOTOPE LABELING; LUNG CANCER; MOLECULAR IMAGING; NEOPLASM; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER;

EID: 84861858548     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800609751     Document Type: Article

References (178)

1. Landais, P.; Méresse, V.; Ghislain, J.-C. Evaluation and Validation of Diagnostic Tests for Guiding Therapeutic Decisions. Thérapie 2009. 64(3), 195-201.
2. Rudin, M.; Kim, E.E. Imaging in Drug Discovery and Early Clinical Trials. J. Nucl. Med., 2007. 48(6), 1037.
3. Willmann, J.K.; van Bruggen, N.; Dinkelborg, L.M.; Gambhir, S.S. Molecular imaging in drug development. Nat. Rev. Drug Discov., 2008. 7(7), 591-607.
4. Haberkorn, U.; Eisenhut, M. Molecular imaging and therapy - a programme based on the development of new biomolecules. Eur. J. Nucl. Med. Mol. Imaging, 2005. 32(12), 1354-9.
5. Ametamey, S.M.; Honer, M.; Schubiger, P.A. Molecular Imaging with PET. Chem. Rev., 2008. 108(5), 1501-16.
6. Hargreaves, R.J. The Role of Molecular Imaging in Drug Discovery and Development. Clin. Pharmacol. Ther., 2008. 83(2), 349-53.
7. Massoud, T.F.; Gambhir, S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev., 2003. 17(5), 545-80.
8. Frangioni, J.V. New technologies for human cancer imaging. J. Clin. Oncol., 2008. 26(24), 4012-21.
9. Zoller, F.; Eisenhut, M.; Haberkorn, U.; Mier, W. Endoradiotherapy in cancer treatment - Basic concepts and future trends. Eur. J. Pharmacol., 2009. 625(1-3), 55-62.
10. Metzler-Nolte, N. Labeling of Biomolecules for Medicinal Applications - Bioorganometallic Chemistry at Its Best. Angew. Chem. Int. Ed. Engl., 2001. 40(6), 1040-3.
11. Guo, Z.; Sadler, P.J. Metals in Medicine. Angew. Chem. Int. Ed. Engl., 1999. 38(11), 1512-31.
12. Liu, S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Deliv. Rev., 2008. 60(12), 1347-70.
13. Ando, A.; Ando, I.; Hiraki, T.; Hisada, K. Relation between the location of elements in the periodic table and various organ-uptake rates. Int. J. Rad. Appl. Instrum. B., 1989. 16(1), 57-80.
14. Heppeler, A.; Froidevaux, S.; Mäcke, H.R.; Jermann, E.; Béhé, M.; Powell, P.; Hennig, M. Radiometal-Labeled Macrocyclic Chelator-Derivatised Somatostatin Analog with Superb Tumor-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy. Chem. Eur. J., 1999. 5(7), 1974-81.
15. Liu, S.; Edwards, D., Fundamentals of Receptor-Based Diagnostic Metalloradiopharmaceuticals, in Topics in Current Chemistry: Contrast Agents II, W. Krause, Editor. 2002, Springer-Verlag: Berlin /Heidelberg. p. 259-78.
16. Liu, S. The role of coordination chemistry in the development of targetspecific radiopharmaceuticals. Chem. Soc. Rev., 2004. 33(7), 445-61.
17. Liu, S.; Edwards, D.S. Bifunctional Chelators for Therapeutic Lanthanide Radiopharmaceuticals. Bioconjug. Chem., 2001. 12(1), 7-34.
18. Reichert, D.E.; Lewis, J.S.; Anderson, C.J. Metal complexes as diagnostic tools. Coord. Chem. Rev., 1999. 184 3-66.
19. Anderson, C.J.; Welch, M.J. Radiometal-Labeled Agents (Non-Technetium) for Diagnostic Imaging. Chem. Rev., 1999. 99(9), 2219-34.
20. Liu, W.; Hao, G.; Long, M.A.; Anthony, T.; Hsieh, J.-T.; Sun, X. Imparting Multivalency to a Bifunctional Chelator: A Scaffold Design for Targeted PET Imaging Probes. Angew. Chem. Int. Ed. Engl., 2009. 48(40), 7346-9.
21. Audrain, H. Positron Emission Tomography (PET) and Microfluidic Devices: A Breakthrough on the Microscale? Angew. Chem. Int. Ed. Engl., 2007. 46(11), 1772-5.
22. Wadas, T.J.; Wong, E.H.; Weisman, G.R.; Anderson, C.J. Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease. Chem. Rev., 2010. 110(5), 2858-902.
23. Miller, P.; Long, N.; Vilar, R.; Gee, A. Synthesis of 11C, 18F, 15O, and 13N Radiolabels for Positron Emission Tomography. Angew. Chem. Int. Ed. Engl., 2008. 47(47), 8998-9033.
24. Mier, W.; Hoffend, J.; Haberkorn, U.; Eisenhut, M., Current Strategies in Tumor-Targeting, in Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases, M. Los and S.B. Gibson, Editors. 2005, Springer US: New York. p. 343-55.
25. Chatal, J.F.; Hoefnagel, C.A. Radionuclide therapy. Lancet, 1999. 354(9182), 931-5.
26. Hakenberg, O.W. Brachytherapy for prostate cancer in 2010. Panminerva Med., 2010. 52(3), 183-8.
27. Wohlgemuth, W.A.; Leissner, G.; Wengenmair, H.; Bohndorf, K.; Kirchhof, K. Endovascular brachytherapy with 192Ir and 188Re to treat de novo and recurrent infrainguinal restenoses. J Cardiovasc Surg (Torino), 2010. 51(4), 573-8.
28. Okarvi, S.M. Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases. Med. Res. Rev., 2004. 24(3), 357-97.
29. Okarvi, S.M. Recent developments in 99mTc-labeled peptide-based radiopharmaceuticals: an overview. Nucl. Med. Commun., 1999. 20(12), 1093-112.
30. Liu, M.; Guo, Y.M.; Yang, J.L.; Wang, P.; Zhao, L.Y.; Shen, N.; Wang, S.C.; Guo, X.J.; Wu, Q.F. Application of Cell Penetrating Peptide in Magnetic Resonance Imaging of Bone Marrow Mesenchymal Stem Cells. Acta Biochim. Biophys. Sin. (Shanghai), 2006. 38(12), 865-73.
31. Jeger, S.; Zimmermann, K.; Blanc, A.; Grünberg, J.; Honer, M.; Hunziker, P.; Struthers, H.; Schibli, R. Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase. Angew. Chem. Int. Ed. Engl., 2010. 49(51), 9995-7.
32. Giné, E.; Gutiérrez-García, G.; López- Guillermo, A. Current immunochemotherapy strategies in follicular lymphoma. Adv. Ther., 2010. 27(10), 704-13.
33. Mindt, T.L.; Jungi, V.; Wyss, S.; Friedli, A.; Pla, G.; Novak-Hofer, I.; Grunberg, J.; Schibli, R. Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase. Bioconjug. Chem., 2008. 19(1), 271-8.
34. Yu, R. Radiotherapy: Radioactive somatostatin analog therapy against carcinoids. Nat Rev Endocrinol, 2010. 6(8), 428-30.
35. Rolleman, E.; Melis, M.; Valkema, R.; Boerman, O.; Krenning, E.; de Jong, M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogs. Eur. J. Nucl. Med. Mol. Imaging, 2010. 37(5), 1018-31.
36. Nanda, P.K.; Lane, S.R.; Retzloff, L.B.; Pandey, U.S.; Smith, C.J. Radiolabeled regulatory peptides for imaging and therapy. Curr. Opin. Endocrinol. Diabetes Obes., 2010. 17(1), 69-76.
37. Wangler, C.; Buchmann, I.; Eisenhut, M.; Haberkorn, U.; Mier, W. Radiolabeled peptides and proteins in cancer therapy. Protein Pept. Lett., 2007. 14(3), 273-9.
38. Gabriel, M.; Decristoforo, C.; Maina, T.; Nock, B.; vonGuggenberg, E.; Cordopatis, P.; Moncayo, R. 99mTc-N4-[Tyr3]Octreotate Versus 99mTc- EDDA/HYNIC-[Tyr3]Octreotide: An Intrapatient Comparison of Two Novel Technetium-99m Labeled Tracers for Somatostatin Receptor Scintigraphy. Cancer Biother. Radiopharm., 2004. 19(1), 73-9.
39. Weiner, R.E.; Thakur, M.L. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl. Radiat. Isot., 2002. 57(5), 749-63.
40. Schibli, R.; Schubiger, A. Current use and future potential of organometallic radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging, 2002. 29(11), 1529-42.
41. Langer, M.; Beck-Sickinger, A.G. Peptides as carrier for tumor diagnosis and treatment. Curr. Med. Chem. Anticancer Agents, 2001. 1(1), 71-93.
42. Bangard, M.; Béhé, M.; Guhlke, S.; Otte, R.; Bender, H.; Maecke, H.R.; Biersack, H.J. Detection of somatostatin receptor-positive tumors using the new 99mTc-tricine-HYNIC-d -Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-d -Phe1-octreotide. Eur. J. Nucl. Med. Mol. Imaging, 2000. 27(6), 628-37.
43. Vallabhajosula, S.; Moyer, B.R.; Lister-James, J.; McBride, B.J.; Lipszyc, H.; Lee, H.; Bastidas, D.; Dean, R.T. Preclinical Evaluation of Technetium- 99m-Labeled Somatostatin Receptor-Binding Peptides. J. Nucl. Med., 1996. 37(6), 1016-22.
44. Merrifield, R.B. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J. Am. Chem. Soc., 1963. 85(14), 2149-54.
45. Thakur, M.L. Radiolabeled peptides: now and the future. Nucl. Med. Commun., 1995. 16(9), 724-32.
46. Liu, S.; Edwards, D.S.; Barrett, J.A. 99mTc Labeling of Highly Potent Small Peptides. Bioconjug. Chem., 1997. 8(5), 621-36.
47. Liu, S.; Edwards, D.S. 99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. Chem. Rev., 1999. 99(9), 2235-68.
48. Mier, W.; Eritja, R.; Mohammed, A.; Haberkorn, U.; Eisenhut, M. Preparation and Evaluation of Tumor-Targeting Peptide - Oligonucleotide Conjugates. Bioconjug. Chem., 2000. 11(6), 855-60.
49. Merrifield, R.B. Automated Synthesis of Peptides. Science, 1965. 150(3693), 178-85.
50. Merrifield, R.B.; Stewart, J.M. Automated Peptide Synthesis. Nature, 1965. 207(4996), 522-3.
51. Deutscher, S.L. Phage Display in Molecular Imaging and Diagnosis of Cancer. Chem. Rev., 2010. 110(5), 3196-211.
52. Lindner, T.; Kolmar, H.; Haberkorn, U.; Mier, W. DNA libraries for the construction of phage libraries: statistical and structural requirements and synthetic methods. Molecules, 2011. 16(2), 1625-41.
53. Cuttitta, F. Peptide amidation: Signature of bioactivity. Anat. Rec. (Hoboken), 1993. 236(1), 87-95.
54. Haubner, R.; Wester, H.J.; Burkhart, F.; Senekowitsch-Schmidtke, R.; Weber, W.; Goodman, S.L.; Kessler, H.; Schwaiger, M. Glycosylated RGDcontaining peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med., 2001. 42(2), 326-36.
55. Qu, T.; Wang, Y.; Zhu, Z.; Rusckowski, M.; Hnatowich, D.J. Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm. Nucl. Med. Commun., 2001. 22(2), 203-15.
56. Baidoo, K.E.; Lin, K.-S.; Zhan, Y.; Finley, P.; Scheffel, U.; Wagner, H.N. Design, Synthesis, and Initial Evaluation of High-Affinity Technetium Bombesin Analogs. Bioconjug. Chem., 1998. 9(2), 218-25.
57. Bauer, W.; Briner, U.; Doepfner, W.; Haller, R.; Huguenin, R.; Marbach, P.; Petcher, T.J.; Pless, J. SMS 201-995: A very potent and selective octapeptide analog of somatostatin with prolonged action. Life Sciences, 1982. 31(11), 1133-40.
58. Morschhauser, F.; Radford, J.; Van Hoof, A.; Vitolo, U.; Soubeyran, P.; Tilly, H.; Huijgens, P.C.; Kolstad, A.; d'Amore, F.; Diaz, M.G.; Petrini, M.; Sebban, C.; Zinzani, P.L.; van Oers, M.H.J.; van Putten, W.; Bischof- Delaloye, A.; Rohatiner, A.; Salles, G.; Kuhlmann, J.; Hagenbeek, A. Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. J. Clin. Oncol., 2008. 26(32), 5156-64.
59. Jurisson, S.S.; Lydon, J.D. Potential Technetium Small Molecule Radiopharmaceuticals. Chem. Rev., 1999. 99(9), 2205-18.
60. Mier, W.; Eritja, R.; Mohammed, A.; Haberkorn, U.; Eisenhut, M. Peptide- PNA Conjugates: Targeted Transport of Antisense Therapeutics into Tumors. Angew. Chem. Int. Ed. Engl., 2003. 42(17), 1968-71.
61. Mardirossian, G.; Lei, K.; Rusckowski, M.; Chang, F.; Qu, T.; Egholm, M.; Hnatowich, D.J. In Vivo Hybridization of Technetium-99m-Labeled Peptide Nucleic Acid (PNA). J. Nucl. Med., 1997. 38(6), 907-13.
62. Schlesinger, J.; Koezle, I.; Bergmann, R.; Tamburini, S.; Bolzati, C.; Tisato, F.; Noll, B.; Klussmann, S.; Vonhoff, S.; Wuest, F.; Pietzsch, H.-J.; Steinbach, J. An 86Y-Labeled Mirror-Image Oligonucleotide: Influence of YDOTA Isomers on the Biodistribution in Rats. Bioconjug. Chem., 2008. 19(4), 928-39.
63. Hamoudeh, M.; Kamleh, M.A.; Diab, R.; Fessi, H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv. Drug Deliv. Rev., 2008. 60(12), 1329-46.
64. Chow, T.H.; Lin, Y.Y.; Hwang, J.J.; Wang, H.E.; Tseng, Y.L.; Pang, V.F.; Liu, R.S.; Lin, W.J.; Yang, C.S.; Ting, G. Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J. Nucl. Med., 2009. 50(12), 2073-81.
65. Liu, Y.; Ibricevic, A.; Cohen, J.A.; Cohen, J.L.; Gunsten, S.P.; Frechet, J.M.J.; Walter, M.J.; Welch, M.J.; Brody, S.L. Impact of Hydrogel Nanoparticle Size and Functionalization on in vivo Behavior for Lung Imaging and Therapeutics. Mol. Pharmaceutics, 2009. 6(6), 1891-902.
66. Wangler, C.; Moldenhauer, G.; Eisenhut, M.; Haberkorn, U.; Mier, W. Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity. Bioconjug. Chem., 2008. 19(4), 813-20.
67. Ting, G.; Chang, C.-H.; Wang, H.-E. Cancer Nanotargeted Radiopharmaceuticals for Tumor Imaging and Therapy. Anticancer Res., 2009. 29(10), 4107-18.
68. Liu, S.; Pietryka, J.; Ellars, C.E.; Edwards, D.S. Comparison of Yttrium and Indium Complexes of DOTA-BA and DOTA-MBA: Models for 90Y- and 111In-Labeled DOTA-Biomolecule Conjugates. Bioconjug. Chem., 2002. 13(4), 902-13.
69. Boswell, C.A.; McQuade, P.; Weisman, G.R.; Wong, E.H.; Anderson, C.J. Optimization of labeling and metabolite analysis of copper-64-labeled azamacrocyclic chelators by radio-LC-MS. Nucl. Med. Biol., 2005. 32(1), 29-38.
70. Sarko, D.; Beijer, B.; Garcia Boy, R.; Nothelfer, E.M.; Leotta, K.; Eisenhut, M.; Altmann, A.; Haberkorn, U.; Mier, W. The pharmacokinetics of cellpenetrating peptides. Mol. Pharmaceutics, 2010. 7(6), 2224-31.
71. Moreau, J.; Guillon, E.; Pierrard, J.-C.; Rimbault, J.; Port, M.; Aplincourt, M. Complexing Mechanism of the Lanthanide Cations Eu3+, Gd3+, and Tb3+ with 1,4,7,10-Tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (DOTA) - Characterization of Three Successive Complexing Phases: Study of the Thermodynamic and Structural Properties of the Complexes by Potentiometry, Luminescence Spectroscopy, and EXAFS. Chemistry, 2004. 10(20), 5218-32.
72. Kukis, D.L.; DeNardo, S.J.; DeNardo, G.L.; O'Donnell, R.T.; Meares, C.F. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J. Nucl. Med., 1998. 39(12), 2105-10.
73. Bartholomä, M.D.; Louie, A.S.; Valliant, J.F.; Zubieta, J. Technetium and Gallium Derived Radiopharmaceuticals: Comparing and Contrasting the Chemistry of Two Important Radiometals for the Molecular Imaging Era. Chem. Rev., 2010. 110(5), 2903-20.
74. Green, M.A.; Welch, M.J. Gallium radiopharmaceutical chemistry. Int. J. Rad. Appl. Instrum. B., 1989. 16(5), 435-43, 45-48.
75. Bruner, H.D.; Hayes, R.L.; Perkinson, J.D., Jr. X. Preliminary data on gallium. Radiology, 1953. 61(4), 602-13.
76. Housecroft, C.E. 4. Yttrium 1993. Coord. Chem. Rev., 1995. 146 A155-A65.
77. Herzog, H.; Rosch, F.; Stocklin, G.; Lueders, C.; Qaim, S.M.; Feinendegen, L.E. Measurement of Pharmacokinetics of Yttrium-86 Radiopharmaceuticals with PET and Radiation Dose Calculation of Analogous Yttrium-90 Radiotherapeutics. J. Nucl. Med., 1993. 34(12), 2222-6.
78. Blower, P.J.; Lewis, J.S.; Zweit, J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl. Med. Biol., 1996. 23(8), 957-80.
79. Blower, P.J.; Prakash, S., The Chemistry of Rhenium in Nuclear Medicine, in Perspectives on Bioinorganic Chemistry, vol. 4, R.W. Hay, J.R. Dilworth and K.B. Nolan, Editors. 1999, JAI Press: London. p. 91-143.
80. Alberto, R.; Abram, U., eds. 99mTc: Labeling Chemistry and Labeled Compounds. In "Handbook of Nuclear Chemistry: Radiochemistry and Radiopharmaceutical Chemistry in Life Sciences". Kluwer Acadimic Publishers: Dorderecht, The Netherlands, 2003.
81. Liu, S. Ether and crown ether-containing cationic 99mTc complexes useful as radiopharmaceuticals for heart imaging. Dalton Trans., 2007(12), 1183-93.
82. Smith, C.J.; Gali, H.; Sieckman, G.L.; Higginbotham, C.; Volkert, W.A.; Hoffman, T.J. Radiochemical Investigations of 99mTc-N3S-X-BBN[7-14]NH2: An in Vitro/in Vivo Structure-Activity Relationship Study Where X = 0-, 3-, 5-, 8-, and 11-Carbon Tethering Moieties. Bioconjug. Chem., 2002. 14(1), 93-102.
83. Papadopoulos, M.; Nock, B.; Maina, T.; Pirmettis, I.; Raptopoulou, C.; Tasiopoulos, A.; Troganis, A.; Kabanos, T.; Terzis, A.; Chiotellis, E. Novel lipophilic amidate oxorhenium and oxotechnetium complexes as potential brain agents: synthesis, characterization and biological evaluation. J. Biol. Inorg. Chem., 2001. 6(2), 159-65.
84. Santos-Cuevas, C.L.; Ferro-Flores, G.; Arteaga de Murphy, C.; Ramírez, F.d.M.; Luna-Gutiérrez, M.A.; Pedraza-López, M.; García-Becerra, R.; Ordaz-Rosado, D. Design, preparation, in vitro and in vivo evaluation of 99mTc-N2S2-Tat(49-57)-bombesin: A target-specific hybrid radiopharmaceutical. Int. J. Pharm., 2009. 375(1-2), 75-83.
85. Karra, S.R.; Schibli, R.; Gali, H.; Katti, K.V.; Hoffman, T.J.; Higginbotham, C.; Sieckman, G.L.; Volkert, W.A. 99mTc-Labeling and in Vivo Studies of a Bombesin Analog with a Novel Water-Soluble Dithiadiphosphine-Based Bifunctional Chelating Agent. Bioconjug. Chem., 1999. 10(2), 254-60.
86. Ossola, F.; Tisato, F.; Refosco, F. Synthetic routes to mono-N-functionalized P2N2-ligands. Inorg. Chim. Acta, 2002. 330(1), 17-24.
87. Zhu, Z.; Wang, Y.; Zhang, Y.; Liu, G.; Liu, N.; Rusckowski, M.; Hnatowich, D.J. A novel and simplified route to the synthesis of N3S chelators for 99mTc labeling. Nucl. Med. Biol., 2001. 28(6), 703-8.
88. Van Domselaar, G.H.; Okarvi, S.M.; Fanta, M.; Suresh, M.R.; Wishart, D.S. Synthesis and 99mTc-labeling of bz-MAG3-triprolinyl-peptides, their radiochemical evaluation and in vitro receptor-binding. J. Labeled Comp. Radiopharm., 2000. 43(12), 1193-204.
89. Lei, K.; Rusckowski, M.; Chang, F.; Qu, T.; Mardirossian, G.; Hnatowich, D.J. Technetium-99m antibodies labeled with MAG3 and SHNH: An in vitro and animal in vivo comparison. Nucl. Med. Biol., 1996. 23(7), 917-22.
90. Shi, J.; Kim, Y.-S.; Chakraborty, S.; Jia, B.; Wang, F.; Liu, S. 2- Mercaptoacetylglycylglycyl (MAG2) as a Bifunctional Chelator for 99mTc- Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics. Bioconjug. Chem., 2009. 20(8), 1559-68.
91. Pearson, D.A.; Lister-James, J.; McBride, W.J.; Wilson, D.M.; Martel, L.J.; Civitello, E.R.; Dean, R.T. Thrombus Imaging Using Technetium-99m- Labeled High-Potency GPIIb/IIIa Receptor Antagonists. Chemistry and Initial Biological Studies. J. Med. Chem., 1996. 39(7), 1372-82.
92. Syhre, R.; Seifert, S.; Spies, H.; Gupta, A.; Johannsen, B. Stability versus reactivity of "3+1" mixed-ligand technetium-99m complexes in vitro and in vivo. Eur. J. Nucl. Med., 1998. 25(7), 793-6.
93. Zhang, J.; Lin, X.; Ren, J.; Liu, J.; Wang, X. Synthesis and biodistribution of a novel 99mTc nitrido dithiocarbamate complex containing aromatic group for cerebral imaging. Appl. Radiat. Isot., 2010. 68(1), 101-4.
94. Boschi, A.; Uccelli, L.; Duatti, A.; Bolzati, C.; Refosco, F.; Tisato, F.; Romagnoli, R.; Baraldi, P.G.; Varani, K.; Borea, P.A. Asymmetrical nitrido Tc-99m heterocomplexes as potential imaging agents for benzodiazepine receptors. Bioconjug. Chem., 2003. 14(6), 1279-88.
95. Boschi, A.; Bolzati, C.; Benini, E.; Malago, E.; Uccelli, L.; Duatti, A.; Piffanelli, A.; Refosco, F.; Tisato, F. A novel approach to the high-specificactivity labeling of small peptides with the technetium-99m fragment [99mTc(N)(PXP)]2+ (PXP = diphosphine ligand). Bioconjug. Chem., 2001. 12(6), 1035-42.
96. Tisato, F.; Bolzati, C.; Porchia, M.; Refosco, F. Contribution of electrospray mass spectrometry for the characterization, design, and development of nitrido technetium and rhenium heterocomplexes as potential radiopharmaceuticals. Mass Spectrom. Rev., 2004. 23(5), 309-32.
97. 3]+. J. Am. Chem. Soc., 2001. 123(13), 3135-6.
98. 3]+ in Bioorganometallic Chemistry: Design, Structure, and in Vitro Affinity of a 5- HT1A Receptor Ligand Labeled with 99mTc. J. Am. Chem. Soc., 1999. 121(25), 6076-7.
99. 3]+ from [99mTcO4]- in Aqueous Solution and Its Reaction with a Bifunctional Ligand. J. Am. Chem. Soc., 1998. 120(31), 7987-8.
100. 3]+ under CO Pressure in Aqueous Media: A Single Sample Story! Angew. Chem. Int. Ed. Engl., 2000. 39(1), 254-6.
101. Winter, M., Organorhenium compounds, in Gmelin handbook of inorganic chemistry. 1989, Springer-Verlag: Berlin, Heidelberg, New York.
102. Waibel, R.; Alberto, R.; Willuda, J.; Finnern, R.; Schibli, R.; Stichelberger, A.; Egli, A.; Abram, U.; Mach, J.-P.; Pluckthun, A.; Schubiger, P.A. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotech., 1999. 17(9), 897-901.
103. 3-labeled N(τ)- histidine folate derivative with its isostructural, clicked 1,2,3-triazole analog. Bioconjug. Chem., 2008. 19(8), 1689-95.
104. Struthers, H.; Spingler, B.; Mindt, T.L.; Schibli, R. "Click-to-chelate": design and incorporation of triazole-containing metal-chelating systems into biomolecules of diagnostic and therapeutic interest. Chemistry, 2008. 14(20), 6173-83.
105. Mindt, T.L.; Struthers, H.; Brans, L.; Anguelov, T.; Schweinsberg, C.; Maes, V.; Tourwe, D.; Schibli, R. "Click to chelate": synthesis and installation of metal chelates into biomolecules in a single step. J. Am. Chem. Soc., 2006. 128(47), 15096-7.
106. Bartholomä, M.; Valliant, J.; Maresca, K.P.; Babich, J.; Zubieta, J. Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals. Chem. Commun., 2009(5), 493-512.
107. Abrams, M.J.; Juweid, M.; tenKate, C.I.; Schwartz, D.A.; Hauser, M.M.; Gaul, F.E.; Fuccello, A.J.; Rubin, R.H.; Strauss, H.W.; Fischman, A.J. Technetium-99m-Human Polyclonal IgG Radiolabeled via the Hydrazino Nicotinamide Derivative for Imaging Focal Sites of Infection in Rats. J. Nucl. Med., 1990. 31(12), 2022-8.
108. Kelly, J.D.; Forster, A.M.; Higley, B.; Archer, C.M.; Booker, F.S.; Canning, L.R.; Chiu, K.W.; Edwards, B.; Gill, H.K.; McPartlin, M.; Nagle, K.R.; Latham, I.A.; Pickett, R.D.; Storey, A.E.; Webbon, P.M. Technetium-99m- Tetrofosmin as a New Radiopharmaceutical for Myocardial Perfusion Imaging. J. Nucl. Med., 1993. 34(2), 222-7.
109. Liu, G.; Hnatowich, D.J. Labeling biomolecules with radiorhenium: a review of the bifunctional chelators. Anticancer Agents Med. Chem., 2007. 7(3), 367-77.
110. Babich, J.W.; Graham Coco, W.; Barrow, S.; Fischman, A.J.; Femia, F.J.; Zubieta, J. 99mTc-labeled chemotactic peptides: influence of coligand on distribution of molecular species and infection imaging properties. Synthesis and structural characterization of model complexes with the {Re(η2- HNNC5H4N)(η1-NNC5H4N)} core. Inorg. Chim. Acta, 2000. 309(1-2), 123-36.
111. Arterburn, J.B.; Rao, K.V.; Goreham, D.M.; Valenzuela, M.V.; Holguin, M.S.; Hall, K.A.; Ott, K.C.; Bryan, J.C. Functionalized Rhenium(V) Organoimido Complexes as Potential Radiopharmaceuticals. 2. Synthesis, Structural Characterization, and Reactivity of N-Succinimidyl Ester Derivatives with Amines. Organometallics, 2000. 19(9), 1789-95.
112. Barandov, A.; Abram, U. Rhenium(V) Complexes with Pentadentate P,N,O Ligands. Inorg. Chem., 2009. 48(17), 8072-4.
113. 3]+ and synthesis of tailor-made bifunctional ligand systems. Bioconjug. Chem., 2002. 13(4), 750-6.
114. Bandoli, G.; Dolmella, A.; Tisato, F.; Porchia, M.; Refosco, F. Mononuclear six-coordinated Ga(III) complexes: A comprehensive survey. Coord. Chem. Rev., 2009. 253(1-2), 56-77.
115. Sun, Y.; Anderson, C.J.; Pajeau, T.S.; Reichert, D.E.; Hancock, R.D.; Motekaitis, R.J.; Martell, A.E.; Welch, M.J. Indium(III) and Gallium(III) Complexes of Bis(aminoethanethiol) Ligands with Different Denticities: Stabilities, Molecular Modeling, and in Vivo Behavior. J. Med. Chem., 1996. 39(2), 2434-.
116. Shannon, R. Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides. Acta Crystallogr., A, 1976. 32(5), 751-67.
117. Riesen, A.; Kaden, T.A.; Ritter, W.; Macke, H.R. Synthesis and X-ray structural characterization of seven co-ordinate macrocyclic In3+ complexes with relevance to radiopharmaceutical applications. J. Chem. Soc. Chem. Commun., 1989(8), 460-2.
118. Weiner, R.E.; Thakur, M.L., Chemistry of Gallium and Indium Radiopharmaceuticals in Handbook of radiopharmaceuticals: radiochemistry and applications, M.J. Welch and C.S. Redvanly, Editors. 2003, John Wiley & Sons: Chichester-West Sussex. p. 363-99.
119. Banin, E.; Lozinski, A.; Brady, K.M.; Berenshtein, E.; Butterfield, P.W.; Moshe, M.; Chevion, M.; Greenberg, E.P.; Banin, E. The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent. Proc. Natl. Acad. Sci. U.S.A., 2008. 105(43), 16761-6.
120. Rösch, F.; Herzog, H.; Stolz, B.; Brockmann, J.; Köhle, M.; Mühlensiepen, H.; Marbach, P.; Müller-Gärtner, H.-W. Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-d Phe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labeled analog. Eur. J. Nucl. Med. Mol. Imaging, 1999. 26(4), 358-66.
121. Carrasquillo, J.A.; White, J.D.; Paik, C.H.; Raubitschek, A.; Le, N.; Rotman, M.; Brechbiel, M.W.; Gansow, O.A.; Top, L.E.; Perentesis, P.; Reynolds, J.C.; Nelson, D.L.; Waldmann, T.A. Similarities and Differences in 111Inand 90Y-Labeled 1B4M-DTPA AntiTac Monoclonal Antibody Distribution. J. Nucl. Med., 1999. 40(2), 268-76.
122. Liu, S.; He, Z.; Hsieh, W.-Y.; Fanwick, P.E. Synthesis, Characterization, and X-ray Crystal Structure of In(DOTA-AA) (AA = p-Aminoanilide): A Model for 111In-Labeled DOTA-Biomolecule Conjugates. Inorg. Chem., 2003. 42(26), 8831-7.
123. Hsieh, W.-Y.; Liu, S. Synthesis, Characterization, and Structures of Indium In(DTPA-BA2) and Yttrium Y(DTPA-BA2)(CH3OH) Complexes (BA = Benzylamine): Models for 111In- and 90Y-Labeled DTPA-Biomolecule Conjugates. Inorg. Chem., 2004. 43(19), 6006-14.
124. Onthank, D.C.; Liu, S.; Silva, P.J.; Barrett, J.A.; Harris, T.D.; Robinson, S.P.; Edwards, D.S. 90Y and 111In Complexes of a DOTA-Conjugated Integrin α vβ3 Receptor Antagonist: Different but Biologically Equivalent. Bioconjug. Chem., 2004. 15(2), 235-41.
125. Ma, R.; Welch, M.J.; Reibenspies, J.; Martell, A.E. Stability of metal ion complexes of 1,4,7-tris(2-mercaptoethyl)-1,4,7-triazacylclonane (TACNTM) and molecular structure of In(C12H24N3S3). Inorg. Chim. Acta, 1995. 236(1-2), 75-82.
126. Bossek, U.; Hanke, D.; Wieghardt, K.; Nuber, B. Pendent arm macrocyclic complexes: crystal structures of AI(TCTA) and In(TS-TACN). Polyhedron, 1993. 12(1), 1-5.
127. Moore, D.A.; Fanwick, P.E.; Welch, M.J. A novel hexachelating amino-thiol ligand and its complex with gallium(III). Inorg. Chem., 1990. 29(4), 672-6.
128. Jones-Wilson, T.M.; Motekaitis, R.J.; Sun, Y.; Anderson, C.J.; Martell, A.E.; Welch, M.J. New hydroxybenzyl and hydroxypyridylmethyl substituted triazacyclononane ligands for use with gallium(III) and indium(III). Nucl. Med. Biol., 1995. 22(7), 859-68.
129. Brechbiel, M.W.; Gansow, O.A.; Atcher, R.W.; Schlom, J.; Esteban, J.; Simpson, D.; Colcher, D. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies. Inorg. Chem., 1986. 25(16), 2772-81.
130. Jarjayes, O.; Mortini, F.; du Moulinet d'Hardemare, A.; Philouze, C.; Serratrice, G. Tuning pGa with Chelating Agents Related to (o- Hydroxybenzyl)iminodiacetic Acid. Eur. J. Inorg. Chem., 2005. 2005(21), 4417-24.
131. Motekaitis, R.J.; Martell, A.E.; Koch, S.A.; Hwang; Quarless, D.A.; Welch, M.J. The Gallium(III) and Indium(III) Complexes of Tris(2- mercaptobenzyl)amine and Tris(2-hydroxybenzyl)amine. Inorg. Chem., 1998. 37(22), 5902-11.
132. Francesconi, L.C.; Liu, B.-L.; Billings, J.J.; Carroll, P.J.; Graczyk, G.; Kung, H.F. Synthesis, characterization and solid state structure of a neutral gallium(III) amino thiolate complex: a potential radiopharmaceutical for PET imaging. J. Chem. Soc. Chem. Commun., 1991(2), 94-5.
133. Li, Y.; Martell, A.E.; Hancock, R.D.; Reibenspies, J.H.; Anderson, C.J.; Welch, M.J. N,Ń-Ethylenedi-l-cysteine (EC) and Its Metal Complexes: Synthesis, Characterization, Crystal Structures, and Equilibrium Constants. Inorg. Chem., 1996. 35(2), 404-14.
134. Wei, L.; Zhang, X.; Gallazzi, F.; Miao, Y.; Jin, X.; Brechbiel, M.W.; Xu, H.; Clifford, T.; Welch, M.J.; Lewis, J.S.; Quinn, T.P. Melanoma imaging using 111In-, 86Y- and 68Ga-labeled CHX-A"-Re(Arg11)CCMSH. Nucl. Med. Biol., 2009. 36(4), 345-54.
135. Govindan, S.V.; Michel, R.B.; Griffiths, G.L.; Goldenberg, D.M.; Mattes, M.J. Deferoxamine as a chelator for 67Ga in the preparation of antibody conjugates. Nucl. Med. Biol., 2005. 32(5), 513-9.
136. Ye, Y.; Liu, M.; Kao, J.L.F.; Marshall, G.R. Novel trihydroxamatecontaining peptides: Design, synthesis, and metal coordination. Peptide Science, 2006. 84(5), 472-89.
137. Chinn, P.; Braslawsky, G.; White, C.; Hanna, N. Antibody therapy of non- Hodgkin's B-cell lymphoma. Cancer Immunol. Immunother., 2003. 52(5), 257-80.
138. Milenic, D.E.; Garmestani, K.; Chappell, L.L.; Dadachova, E.; Yordanov, A.; Ma, D.; Schlom, J.; Brechbiel, M.W. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl. Med. Biol., 2002. 29(4), 431-42.
139. Brechbiel, M.W.; Gansow, O.A. Synthesis of C-functionalized transcyclohexyldiethylenetriaminepenta- acetic acids for labeling of monoclonal antibodies with the bismuth-212 α -particle emitter. J. Chem. Soc. Perkin Trans. I, 1992(9), 1173-8.
140. Wu, C.; Kobayashi, H.; Sun, B.; Yoo, T.M.; Paik, C.H.; Gansow, O.A.; Carrasquillo, J.A.; Pastan, I.; Brechbiel, M.W. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg. Med. Chem., 1997. 5(10), 1925-34.
141. 2O. Rare Met., 2000. 19(4), 241-7.
142. 2O. Journal of organic chemistry of the USSR, 1997. 42(6), 969-71.
143. 2O)](CF3SO3). Inorg. Chim. Acta, 1996. 246(1-2), 99-107.
144. Sun, Y.; Martell, A.E.; Motekaitis, R.J.; Welch, M.J. Synthesis and stabilities of the Ga(III) and In(III) chelates of a new diaminodithiol bifunctional ligand. Tetrahedron, 1998. 54(17), 4203-10.
145. Sun, Y.; Martell, A.E.; Welch, M.J. Synthesis of a New Diaminodithiol Bifunctional Chelator for Radiolabeling Biomolecules with Indium(III). Tetrahedron, 2000. 56(29), 5093-103.
146. Kang, J.-G.; Na, M.-K.; Yoon, S.-K.; Sohn, Y.; Kim, Y.-D.; Suh, I.-H. Determination of the structure of EuTETA and the luminescence properties of EuTETA and EuDOTA (TETA=1,4,8,11-tetraazacyclotetradecane- 1,4,8,11-tetraacetate and DOTA=1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetate). Inorg. Chim. Acta, 2000. 310(1), 56-64.
147. Miller, M.J. Syntheses and therapeutic potential of hydroxamic acid based siderophores and analogs. Chem. Rev., 1989. 89(7), 1563-79.
148. P. Andre, J.; R. Maecke, H.; P. Andre, J.; Zehnder, M.; Macko, L.; G. Akyel, K. 1,4,7-Triazacyclononane-1-succinic acid-4,7-diacetic acid (NODASA): a new bifunctional chelator for radio gallium-labeling of biomolecules. Chem. Commun., 1998(12), 1301-2.
149. Eisenwiener, K.-P.; Prata, M.I.M.; Buschmann, I.; Zhang, H.-W.; Santos, A.C.; Wenger, S.; Reubi, J.C.; Mäcke, H.R. NODAGATOC, a New Chelator-Coupled Somatostatin Analog Labeled with [67/68Ga] and [111In] for SPECT, PET, and Targeted Therapeutic Applications of Somatostatin Receptor (hsst2) Expressing Tumors. Bioconjug. Chem., 2002. 13(3), 530-41.
150. Clarke, E.T.; Martell, A.E. Stabilities of the Fe(III), Ga(III) and In(III) chelates of N,N',N"-triazacyclononanetriacetic acid. Inorg. Chim. Acta, 1991. 181(2), 273-80.
151. Guerin, B.; Ait-Mohand, S.; Tremblay, M.-C.; Dumulon-Perreault, V.; Fournier, P.; Benard, F.o. Total Solid-Phase Synthesis of NOTAFunctionalized Peptides for PET Imaging. Org. Lett., 2009. 12(2), 280-3.
152. Fani, M.; André, J.P.; Mäcke, H.R. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol. Imaging, 2008. 3(2), 53-63.
153. Moi, M.K.; Yanuck, M.; Deshpande, S.V.; Hope, H.; DeNardo, S.J.; Meares, C.F. X-ray crystal structure of a macrocyclic copper chelate stable enough for use in living systems: copper(II) dihydrogen 6-(p-nitrobenzyl)-1,4,8,11- tetraazacyclotetradecane-1,4,8,11-tetraacetate. Inorg. Chem., 1987. 26(21), 3458-63.
154. Garmestani, K.; Yao, Z.; Zhang, M.; Wong, K.; Park, C.W.; Pastan, I.; Carrasquillo, J.A.; Brechbiel, M.W. Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides. Nucl. Med. Biol., 2001. 28(4), 409-18.
155. Clarke, E.T.; Martell, A.E. Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocycles. Inorg. Chim. Acta, 1991. 190(1), 37-46.
156. Cole, E.; Copley, R.C.B.; Howard, J.A.K.; Parker, D.; Ferguson, G.; Gallagher, J.F.; Kaitner, B.; Harrison, A.; Royle, L. 1,4,7- Triazacyclononane-1,4,7-triyltrimethylenetris-(phenylphosphinate) enforces octahedral geometry: crystal and solution structures of its metal complexes and comparative biodistribution studies of radiolabeled indium and gallium complexes. Dalton Trans., 1994(11), 1619-29.
157. Kodama, M.; Koike, T.; Mahatma, A.B.; Kimura, E. Thermodynamic and kinetic studies of lanthanide complexes of 1,4,7,10,13- pentaazacyclopentadecane-N,N',N",N"',N""-pentaacetic acid and 1,4,7,10,13,16-hexaazacyclooctadecane-N,N',N",N"',N"", N""'-hexaacetic acid. Inorg. Chem., 1991. 30(6), 1270-3.
158. Delgado, R.; da Silva, J.J.R.F. Metal complexes of cyclic tetra-azatetra-acetic acids. Talanta, 1982. 29(10), 815-22.
159. Caravan, P.; Ellison, J.J.; McMurry, T.J.; Lauffer, R.B. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem. Rev., 1999. 99(9), 2293-352.
160. Milenic, D.E.; Garmestani, K.; Brady, E.D.; Albert, P.S.; Abdulla, A.; Flynn, J.; Brechbiel, M.W. Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease. Clin. Cancer Res., 2007. 13(6), 1926-35.
161. Chappell, L.L.; Dadachova, E.; Milenic, D.E.; Garmestani, K.; Wu, C.; Brechbiel, M.W. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl. Med. Biol., 2000. 27(1), 93-100.
162. Chong, H.-s.; Garmestani, K.; Ma, D.; Milenic, D.E.; Overstreet, T.; Brechbiel, M.W. Synthesis and Biological Evaluation of Novel Macrocyclic Ligands with Pendent Donor Groups as Potential Yttrium Chelators for Radioimmunotherapy with Improved Complex Formation Kinetics. J. Med. Chem., 2002. 45(16), 3458-64.
163. Cantorias, M.V.; Figueroa, S.D.; Quinn, T.P.; Lever, J.R.; Hoffman, T.J.; Watkinson, L.D.; Carmack, T.L.; Cutler, C.S. Development of high-specificactivity 68Ga-labeled DOTA-rhenium-cyclized α-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors. Nucl. Med. Biol., 2009. 36(5), 505-13.
164. Eisenwiener, K.-P.; Powell, P.; Mäcke, H.R. A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labeling. Bioorg. Med. Chem. Lett., 2000. 10(18), 2133-5.
165. Lewis, M.R.; Kao, J.Y.; Anderson, A.L.; Shively, J.E.; Raubitschek, A. An improved method for conjugating monoclonal antibodies with Nhydroxysulfosuccinimidyl DOTA. Bioconjug. Chem., 2001. 12(2), 320-4.
166. Hoffend, J.; Mier, W.; Schuhmacher, J.; Schmidt, K.; Dimitrakopoulou- Strauss, A.; Strauss, L.G.; Eisenhut, M.; Kinscherf, R.; Haberkorn, U. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nucl. Med. Biol., 2005. 32(3), 287-92.
167. Blom, E.; Langstrom, B.; Velikyan, I. 68Ga-Labeling of Biotin Analogs and their Characterization. Bioconjug. Chem., 2009. 20(6), 1146-51.
168. De Leon-Rodrigues, L.M.; Kovacs, Z. The Synthesis and Chelation Chemistry of DOTA-Peptide Conjugates. Bioconjug. Chem., 2008. 19(2), 391-402.
169. Kruper, W.J.; Rudolf, P.R.; Langhoff, C.A. Unexpected selectivity in the alkylation of polyazamacrocycles. J. Org. Chem., 1993. 58(15), 3869-76.
170. Pippin, C.G.; Parker, T.A.; McMurry, T.J.; Brechbiel, M.W. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug. Chem., 1992. 3(4), 342-5.
171. Mier, W.; Hoffend, J.; Kramer, S.; Schuhmacher, J.; Hull, W.E.; Eisenhut, M.; Haberkorn, U. Conjugation of DOTA Using Isolated Phenolic Active Esters: The Labeling and Biodistribution of Albumin as Blood Pool Marker. Bioconjug. Chem., 2005. 16(1), 237-40.
172. Li, M.; Meares, C.F.; Salako, Q.; Kukis, D.L.; Zhong, G.R.; Miers, L.; DeNardo, S.J. Prelabeling of chimeric monoclonal antibody L6 with 90Yttrium- and 111Indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'- tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy. Cancer Res., 1995. 55(23 Suppl), 5726s-8s.
173. Edman, P. A method for the determination of amino acid sequence in peptides. Arch. Biochem., 1949. 22(3), 475.
174. Lewis, M.R.; Shively, J.E. Maleimidocysteineamido-DOTA Derivatives: New Reagents for Radiometal Chelate Conjugation to Antibody Sulfhydryl Groups Undergo pH-Dependent Cleavage Reactions. Bioconjug. Chem., 1998. 9(1), 72-86.
175. Greupink, R.; Sio, C.; Ederveen, A.; Orsel, J. Evaluation of a 99mTc-Labeled AnnexinA5 Variant for Non-invasive SPECT Imaging of Cell Death in Liver, Spleen and Prostate Pharm. Res., 2009. 26(12), 2647-56.
176. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem. Int. Ed. Engl., 2002. 41(14), 2596-9.
177. Mindt, T.L.; Müller, C.; Stuker, F.; Salazar, J.-F.; Hohn, A.; Mueggler, T.; Rudin, M.; Schibli, R. A "Click Chemistry" Approach to the Efficient Synthesis of Multiple Imaging Probes Derived from a Single Precursor. Bioconjug. Chem., 2009. 20(10), 1940-9.
178. Struthers, H.; Mindt, T.L.; Schibli, R. Metal chelating systems synthesized using the copper(i) catalyzed azide-alkyne cycloaddition. Dalton Trans., 2010. 39(3), 675-96.